Cargando…
Safety of COVID-19 vaccination in patients with clonal mast cell disorders
Autores principales: | Ruano-Zaragoza, Maria, Carpio-Escalona, Laura V., Diaz-Beya, Marina, Piris-Villaespesa, Miguel, Castaño-Diez, Sandra, Muñoz-Cano, Rosa, González-de-Olano, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806141/ https://www.ncbi.nlm.nih.gov/pubmed/35121156 http://dx.doi.org/10.1016/j.jaip.2022.01.030 |
Ejemplares similares
-
Insights in Anaphylaxis and Clonal Mast Cell Disorders
por: González-de-Olano, David, et al.
Publicado: (2017) -
Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
por: González-de-Olano, David, et al.
Publicado: (2016) -
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2020) -
Immune-Mediated Mechanisms in Cofactor-Dependent Food Allergy and Anaphylaxis: Effect of Cofactors in Basophils and Mast Cells
por: Muñoz-Cano, Rosa, et al.
Publicado: (2021) -
Recent advances in mast cell clonality and anaphylaxis
por: Akin, Cem
Publicado: (2009)